Ann: Azer-cel Accepted for Presentation at ASTCT Tandem Meetings, page-13

Read the poster preso title it tells you everything you need to know - they are going to be talking about the enhancement of pharmacokinetics of the drug due to adding IL2.

Here is the title...

Absract title: Administration of Low-Dose, Subcutaneous (SC) Interleukin-2 (IL-2) Markedly Enhances the Pharmacokinetic (PK) Profile of Azercabtagene Zapreleucel (azer-cel), an Allogeneic Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy,

without Compromising Safety and Early Evidence of Clinical Activity in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Who Have Relapsed after Prior CD19-Directed

CAR T-Cell Products.

Doesn't mean it's bad - it's just early stages - so don't get too excited - there will not be any new efficacy data etc.

How do I know? Cause the title tells you what they are presenting.